Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

Gilead, its investors, and AIDS activists have high hopes for Yeztugo. Approved in June for people at high risk of HIV, the drug was shown to be nearly 100% effective at preventing infection in large ...

"In a technology-driven climate, effort should be made to recognize that receiving buprenorphine prescriptions from a ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

Trump said this week that there would be no new extensions granted for the August 1 deadline. Market pros tell BI where they see winners and losers.

Kraft Heinz Co. is preparing to break itself up, people familiar with the matter said, as the US food company looks to combat shifting consumer sentiment and reverse a sagging share price.

Traders have repeatedly shrugged off President Trump’s disruptive tariff wars and fiscal policy, pushing U.S. stock prices back into expensive territory, our columnist says.

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

When an onsite, licensed pharmacy is available, sterile medications, i.v. admixtures, and other drugs are compounded or admixed only in the pharmacy, except in emergencies or when this practice is ...

After all, Stock Advisor’s total average return is 995%* — a market-crushing outperformance compared to 173% for the S&P 500.